Atara Biotherapeutics, Inc.
ATRA
$14.02
$1.4711.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -80.35% | -82.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -80.35% | -82.09% | |||
| Cost of Revenue | 446.03% | -98.60% | |||
| Gross Profit | -97.49% | -70.97% | |||
| SG&A Expenses | -33.02% | -40.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -45.55% | -74.05% | |||
| Operating Income | -175.15% | -90.29% | |||
| Income Before Tax | -278.87% | -93.71% | |||
| Income Tax Expenses | 833.33% | -- | |||
| Earnings from Continuing Operations | -280.27% | -93.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -280.27% | -93.72% | |||
| EBIT | -175.15% | -90.29% | |||
| EBITDA | -156.83% | -88.86% | |||
| EPS Basic | -262.08% | -94.46% | |||
| Normalized Basic EPS | -197.61% | -92.78% | |||
| EPS Diluted | -268.42% | -94.57% | |||
| Normalized Diluted EPS | -198.49% | -92.79% | |||
| Average Basic Shares Outstanding | 11.21% | 13.31% | |||
| Average Diluted Shares Outstanding | 10.19% | 13.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||